Recent

% | $
Quotes you view appear here for quick access.

Alnylam Pharmaceuticals, Inc. Message Board

  • techmgr2001 techmgr2001 Oct 8, 2004 3:26 PM Flag

    analyst coverage

    I see that alny has 2 analysts already. How does an analyst truly cover a company in preclinical development? Have they a new crystal ball regarding the outcome of experiments not yet done? At least one of them was neutral, but one outperform? Outperform what - their experiments will work better than others experiments?

    RNAi looks promising. However, developing a profitable product is a long hard road as I and my colleagues in biotech are aware. Making it through clinical trials to market is a long way off in the future.

    In the chemical industry the saw is "test tubes to tank cars = ten years". Biotech is longer still - how about "cell culture to syringes = seventeen years".

 
ALNY
57.00-2.22(-3.75%)Feb 10 4:00 PMEST